Surgery plus osimertinib for advanced EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage III or IV non-squamous non-small cell lung cancer that cannot be removed with surgery alone.
- Your cancer has an EGFR mutation called exon 19 deletion or L858R.
- You have not had any prior systemic treatment for lung cancer.
- You are in good physical condition (ECOG score 0 or 1).
- Your main lung tumor is at least 1 cm, and you have at least one other measurable tumor that remains after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving osimertinib together with chemotherapy before surgery can shrink and control EGFR-mutant, stage III lung cancer so it can be fully removed. If it works, it may improve the chances that the cancer does not come back after surgery.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether adding a new drug (SYS6010) to the standard targeted therapy osimertinib before surgery can help shrink EGFR-positive lung tumors more than osimertinib alone. It is for people with early-stage (II to IIIB) non-small cell lung cancer that can be removed surgically.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.